Compare ACIC & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ACIC | ERAS |
|---|---|---|
| Founded | 1999 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 473.4M | 6.3B |
| IPO Year | 2007 | 2021 |
| Metric | ACIC | ERAS |
|---|---|---|
| Price | $9.77 | $13.60 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 10 |
| Target Price | $13.00 | ★ $25.10 |
| AVG Volume (30 Days) | 183.5K | ★ 5.1M |
| Earning Date | 10-29-2026 | 11-12-2026 |
| Dividend Yield | ★ 7.64% | N/A |
| EPS Growth | ★ 39.61 | 36.23 |
| EPS | ★ 1.23 | N/A |
| Revenue | ★ $335,439,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $7.98 | ★ N/A |
| Revenue Growth | ★ 13.07 | N/A |
| 52 Week Low | $9.01 | $2.81 |
| 52 Week High | $13.06 | $24.28 |
| Indicator | ACIC | ERAS |
|---|---|---|
| Relative Strength Index (RSI) | 37.07 | 42.80 |
| Support Level | $9.06 | $13.18 |
| Resistance Level | $11.49 | $15.71 |
| Average True Range (ATR) | 0.36 | 1.31 |
| MACD | -0.11 | -0.13 |
| Stochastic Oscillator | 12.59 | 14.12 |
American Coastal Insurance Corp is a holding company that underwrites commercial residential property and casualty insurance policies in the United States through its wholly-owned insurance subsidiary.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its focused RAS/MAPK pathway pipeline comprises modality-agnostic programs aligned with three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes two clinical-stage programs (ERAS-0015, a pan-RAS molecular glue; and ERAS-4001, a pan-KRAS inhibitor), and ERAS-12, a discovery-stage program.